Gaudium IVF

Why is Gaudium IVF and Women Health Ltd falling/rising?

As of 13-Jul, Gaudium IVF and Women Health Ltd's stock price is rising, currently at Rs 129.30, reflecting a 3.77% increase. The stock has shown strong performance with a 30.41% rise over the past month, outperforming the Sensex, although there are signs of decreasing investor participation.

As of 13-Jul, Gaudium IVF and Women Health Ltd's stock price is rising, currently at Rs 129.30, which reflects an increase of Rs 4.7 or 3.77%. The stock has shown strong performance over the past week, gaining 5.25% compared to a decline of 0.85% in the Sensex. Over the past month, the stock has surged by 30.41%, significantly outperforming the Sensex's increase of 2.77%. <BR><BR>Today, the stock has outperformed its sector by 4.43% and has been on a consecutive gain streak for the last three days, accumulating a total return of 14.94% during this period. The stock also approached its 52-week high, being only 2.31% away from the high of Rs 133. Additionally, it reached an intraday high of Rs 130, marking a rise of 4.33% during the day.<BR><BR>Despite these positive indicators, there are some signs of falling investor participation, with delivery volume decreasing by 24.04% against the 5-day average. However, the stock remains liquid enough for trading, indicating that while interest may be waning, the stock's overall upward trajectory is supported by strong recent performance and favorable comparisons to market benchmarks.

Which are the latest news on Gaudium IVF?

Should I buy, sell or hold Gaudium IVF and Women Health Ltd?

What does Gaudium IVF do?

Gaudium IVF and Women Health Ltd is a micro-cap healthcare services company specializing in IVF treatments, with recent net sales of 30 Cr and a net profit of 8 Cr as of March 2026. Key financial metrics include a P/E ratio of 27.00 and a market cap of INR 766 Cr.

Overview: <BR>Gaudium IVF and Women Health Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not provided. The latest quarterly results reported are for March 2026, showing net sales and profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 30 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 8 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 766 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.10 <BR>Return on Equity: 16.08% <BR>Price to Book: 5.03 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Gaudium IVF?

As of 10th June, Gaudium IVF and Women Health Ltd has a market capitalization of 766.00 Cr, with recent net sales of 113.51 Cr and a net profit of 27.83 Cr. The balance sheet for March 2025 shows shareholder's funds of 46.30 Cr and total assets of 88.51 Cr.

As of 10th June, Gaudium IVF and Women Health Ltd has a market capitalization of 766.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Gaudium IVF reported Net Sales of 113.51 Cr and a Net Profit of 27.83 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 46.30 Cr and Total Assets of 88.51 Cr.

Who are the peers of the Gaudium IVF?

Gaudium IVF's peers include Tarsons Products, One Global Serv, 3B Blackbio, Health X Platfor, Hemant Surgical, Prevest Denpro, Take Solutions, and Nureca. Hemant Surgical has the highest 1-year return at 278.57%, while Tarsons Products has the lowest at -45.32%.

Peers: The peers of Gaudium IVF are Tarsons Products, One Global Serv, 3B Blackbio, Health X Platfor, Hemant Surgical, Prevest Denpro, Take Solutions, and Nureca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prevest Denpro, while Average management risk is found at One Global Serv, 3B Blackbio, and Hemant Surgical, and the rest. Below Average management risk is present in Tarsons Products, Health X Platfor, Take Solutions, and Nureca. For Growth, Excellent growth is noted at One Global Serv, Good growth at Hemant Surgical, and the rest show Below Average or Average growth. In terms of Capital Structure, Excellent capital structure is seen in One Global Serv, 3B Blackbio, Health X Platfor, and Prevest Denpro, while Good capital structure is noted at Tarsons Products and Hemant Surgical, and Below Average capital structure is present in Take Solutions and Nureca.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hemant Surgical at 278.57%, while the lowest is Tarsons Products at -45.32%. Gaudium IVF's 1-year return is not available for comparison. Additionally, several peers, including Take Solutions, Nureca, Prevest Denpro, and others, have negative six-month returns.